Abstract Number: 1108 • ACR Convergence 2025
Baseline Features, Immunosuppression, and Immune-Related Adverse Events in Patients with Pre-existing Rheumatic Disease and Cancer Requiring Immune Checkpoint Inhibitor Therapy
Background/Purpose: Immune checkpoint inhibitors (ICIs) are effective therapies commonly used to treat malignancies but can cause flares or unrelated immune-related adverse events (irAEs) in patients…Abstract Number: 0987 • ACR Convergence 2025
S-4321, a novel dual-cell bifunctional PD-1:FcγRIIb selective agonist antibody for autoimmune disease, maintains expression of PD-1 on target cells and enhances inhibitory receptor expression on T cells in vivo
Background/Purpose: S-4321 is a novel antibody that agonizes the inhibitory PD-1 checkpoint receptor on T cells without competing for binding with its natural ligand, PD-L1,…Abstract Number: 0922 • ACR Convergence 2025
Phenotypic and Transcriptomic Divergence in C3 Glomerular Mouse Models: Insights into Immune and Sex Correlates
Background/Purpose: Complement component C3 plays a central role in the alternative pathway (AP) and is implicated in the pathogenesis of C3 glomerulopathy (C3G), a rare…Abstract Number: 0698 • ACR Convergence 2025
A Retrospective Comparison of Transplant Outcomes with Different Induction Methods and Maintenance Prednisone in Systemic Sclerosis Patients
Background/Purpose: Systemic sclerosis (SSc) or scleroderma is a rare systemic autoimmune disease with multiple organ involvement. Renal involvement in SSc remains a significant concern, with…Abstract Number: 0861 • ACR Convergence 2025
Identification of Anti-HDGFL1 as a Novel Autoantibody in Seronegative Idiopathic Inflammatory Myopathies
Background/Purpose: Myositis-specific autoantibodies (MSAs) play a crucial role in diagnosing and classifying idiopathic inflammatory myopathies (IIMs). However, approximately 30% of seronegative IIM patients may be…Abstract Number: 0431 • ACR Convergence 2025
Calprotectin Serum levels: a potential neutrophil activation biomarker to monitor treatment response in Rheumatoid Arthritis
Background/Purpose: Calprotectin is a protein highly expressed in myeloid cells and its elevated presence in blood, and the GI tract is associated with immune mediated…Abstract Number: 0274 • ACR Convergence 2025
Transplant-free survival in patients with systemic autoimmune rheumatic diseases and progressive pulmonary fibrosis in the ILD-PRO Registry
Background/Purpose: Progressive pulmonary fibrosis (PPF) is known to be associated with high mortality, but there are few data on the course of PPF in patients…Abstract Number: 0235 • ACR Convergence 2025
Mortality Trends due to Hypertension Related Deaths in Elderly Patients with Inflammatory Polyarthropathy: A CDC WONDER Analysis of 21 Years
Background/Purpose: Inflammatory polyarthropathy (IPA) is a group of chronic autoimmune disorders, common among older adults and contribute significantly to systemic inflammation and cardiovascular risk .…Abstract Number: 0125 • ACR Convergence 2025
The IFN Signature is Less Pronounces in Primary Antiphospholipid Syndrome Compared with other Systemic Autoimmune Diseases
Background/Purpose: Primary antiphospholipid syndrome (pAPS) is an autoimmune disease that, unlike many other autoimmune diseases, commonly presents with thrombotic events rather than inflammatory manifestations. A…Abstract Number: 0015 • ACR Convergence 2025
CDR111 is a novel CD19 and BCMA dual-targeting T cell engager (TCE) for the treatment of severe and refractory autoimmune diseases
Background/Purpose: B cells and plasma cells are central to the pathogenesis of many autoimmune diseases. While B cell depletion therapies (BCDTs), such as anti-CD20 monoclonal…Abstract Number: PP08 • ACR Convergence 2025
Living Well Despite the Challenges of Sjögren’s Disease and Systemic Lupus Erythematous: My Perspective as a Health Care Provider and Patient
Background/Purpose: Typically, the diagnosis of any autoimmune condition can be challenging and take years. In my case, my diagnosis of Sjögren's disesase (SjD) was established…Abstract Number: 2601 • ACR Convergence 2025
Characterisation of immunometabolic reprogramming at the single cell level in patients with systemic lupus erythematosus and preclinical autoimmunity
Background/Purpose: Systemic lupus erythematosus (SLE) is characterised by innate immune activation and autoantibodies against nucleic self-antigens. The metabolic state of immune cells is emerging as…Abstract Number: 2500 • ACR Convergence 2025
Greater Economic Burden and Healthcare Resource Utilization in Patients with Systemic Sclerosis With Versus Without Interstitial Lung Disease: Results from a Systematic Literature Review
Background/Purpose: SSc is a rare autoimmune connective tissue disorder; up to 64% of patients with SSc develop interstitial lung disease (ILD), which can result in…Abstract Number: 2397 • ACR Convergence 2025
Analytical Performance of a Fully Automated Multiplexed Microarray Immunoassay for the Simultaneous Detection of Fifteen Autoantibodies Associated with Connective Tissue Diseases in a Reference Laboratory in Southern France
Background/Purpose: Autoantibodies are key diagnostic markers in autoimmune connective tissue diseases (CTD). Conventional testing often requires multiple single-measurand assays, which can be labor-intensive and time-consuming.…Abstract Number: 2027 • ACR Convergence 2025
Development of a multi-disease panel for autoimmune diseases
Background/Purpose: Autoantibodies serve as important biomarkers for diagnosing autoimmune diseases. However, current clinical assays for their detection often face challenges, such as uncertainty about the…
- « Previous Page
- 1
- …
- 9
- 10
- 11
- 12
- 13
- …
- 101
- Next Page »